UK MHRA Approves Deciphera's Vimseltinib (Romvimza) for Tenosynovial Giant Cell Tumour
核心洞察
The UK MHRA granted marketing authorization to vimseltinib (Romvimza) on 14 August 2026 for adult patients with tenosynovial giant cell tumour (搜索) (TGCT) affecting movement or unsuitable for surgery.
Vimseltinib, developed by Deciphera Pharmaceuticals (搜索), slows TGCT growth by blocking the proteins that drive tumour growth and is taken as a capsule twice weekly.
The approval provides a new treatment option for patients with symptomatic TGCT who cannot undergo surgery, addressing a significant unmet need in this rare condition.
The Medicines and Healthcare products Regulatory Agency (搜索) (MHRA) has approved vimseltinib (Romvimza) to treat adult patients with tenosynovial giant cell tumour (搜索) (TGCT) when it impacts movement or where surgery is not an option. The marketing authorization was granted on 14 August 2026 to Deciphera Pharmaceuticals (搜索).
TGCT is a rare non-cancerous tumour that forms around a joint and tendons. It usually affects a single joint, most often the knee or ankle of young and middle-aged adults, and can cause symptoms such as pain, swelling, stiffness and difficulty in movement.
Julian Beach, MHRA Executive Director, Healthcare Quality and Access, said: "Keeping patients safe and enabling their access to high quality, safe and effective medical products are key priorities for us. The approval of vimseltinib provides a new treatment option for patients with TGCT who have symptoms but are unsuitable for surgery. As with all products, we will continue to keep the safety of vimseltinib under close review."
Mechanism of Action and Administration
The active ingredient in Romvimza, vimseltinib, helps slow the growth of TGCTs by blocking the proteins that cause these tumours to grow. Vimseltinib is a capsule that should be swallowed whole with water and with or without food, twice a week.
Safety Profile and Monitoring
This medicine is subject to additional monitoring and should not be used in pregnancy. The most common side effects of vimseltinib, which may affect more than 1 in 5 people, include tiredness, swelling around the eyes, ankles and feet, itching, rashes, high blood pressure, increased levels of liver enzymes, increased levels of cholesterol, increased levels of creatinine, and decreased white blood cell levels (neutrophils).
Patients should take vimseltinib exactly as prescribed and discuss any side effects with their doctor or pharmacist. Anyone who suspects they are having a side effect is encouraged to talk to their doctor, pharmacist or nurse and report it directly to the Yellow Card scheme.
Regulatory Pathway
This product was submitted and approved via the International Recognition Procedure (IRP) Route B. The MHRA is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe, with all work underpinned by robust and fact-based judgements to ensure that the benefits justify any risks. The MHRA is an executive agency of the Department of Health and Social Care.